U.S. Industrials Stock News

In recent weeks, Boston Scientific reported strong Q3 2025 results, highlighting robust growth in its cardiovascular product lines and raising its adjusted 2025 EPS outlook. This performance has helped draw in additional institutional investors and keep analysts positive on the company’s prospects despite earlier share price volatility. We’ll now explore how the upgraded earnings outlook and growing institutional interest could influence Boston Scientific’s broader investment narrative...

If you are wondering whether CDW is starting to look like a bargain after a choppy run in tech, this article will walk through whether the current price actually lines up with the company’s fundamentals. CDW shares now trade around $143.08, down 4.5% over the last week and 15.9% year to date, but still up 17.5% over 5 years, which hints at a solid long term story despite recent weakness. Recent sentiment around IT spending, cloud infrastructure rollouts and enterprise digital transformation...

Viasat (VSAT) just reshaped its government business by unveiling a unified global Ka band network that stitches together its own satellites, the Global Xpress fleet, and partners into one interoperable platform. See our latest analysis for Viasat. Those moves come after a huge rerating, with Viasat’s year to date share price return of roughly 240 percent and a 1 year total shareholder return of about 277 percent signaling momentum that, despite recent pullbacks, remains firmly in growth...

If you are wondering whether Lennar is starting to look like a bargain or if it is cheap for a reason, this deep dive will walk through what the current share price really implies. The stock has pulled back recently, down about 9.2% over the last week, 5.9% over the past month, and 19.4% year to date, even though it is still up 56.7% over five years. Some of that weakness has come as investors reassess housing demand in a higher rate environment and rotate out of homebuilders after a strong...

Ciena (CIEN) just delivered a busy earnings day, pairing solid full year growth with a stronger outlook for 2026 that is pulling fresh attention to how quickly its networking story is evolving. See our latest analysis for Ciena. That optimism is showing up in the tape, with Ciena's 1 month share price return of 11.62 percent and 3 month share price return of 52.28 percent contributing to a standout 153.14 percent year to date share price return and a 141.14 percent 1 year total shareholder...

If you are wondering whether PBF Energy is a bargain or a value trap at today’s price, you are not alone. This article will break down what the current market is really implying about the stock. After a 315.8% gain over the last 5 years, the shares have pulled back sharply, down 14.3% over the past week and 30.5% in the last month. The 1 year return still sits at 8.1%, and year to date performance is only a modest -2.8%. Recent headlines have focused on shifting sentiment toward refiners as...

Recent data on Assured Guaranty (AGO) is sending mixed messages, with short interest rising even as management keeps buying back shares and steadily growing book value, which may hint that the market is misreading the story. See our latest analysis for Assured Guaranty. Despite the tug of war between rising short interest and steady buybacks, Assured Guaranty’s 90 day share price return of 10.22 percent and five year total shareholder return of 216.44 percent suggest momentum is quietly...

Kratos Defense & Security Solutions (KTOS) is back in the spotlight after fresh analyst coverage and a string of new facilities, moves that together sharpen the market’s focus on its long term growth runway. See our latest analysis for Kratos Defense & Security Solutions. Those new facilities and upbeat coverage are landing against a backdrop where the $71.4 share price has cooled from recent highs, with a negative 90 day share price return but an eye catching three year total shareholder...

Wondering if Global Payments at around $82 a share is a beaten down opportunity or a value trap? You are not alone, and this article is going to unpack exactly what the market might be missing. After sliding a hefty 26.6% year to date and 24.9% over the last year, the stock has recently bounced about 14.0% in the last month, with only a modest 0.2% move over the last week, hinting that sentiment may be at a turning point. That shift has come as investors refocus on Global Payments strategic...

Assessing Applied Optoelectronics After Its Recent Share Move Applied Optoelectronics (AAOI) has been on a choppy ride lately, jumping about 8% in the latest session but still down for the year. This naturally raises questions about where this story goes next. See our latest analysis for Applied Optoelectronics. That 7.77% 1 day share price gain to around $29.25 comes after a sharp pullback, with a 30 day share price return of 40.02% but a year to date share price return still negative. This...

Pagaya Technologies (PGY) just landed a fresh commercial win, as digital finance player Achieve agreed to plug Pagaya's AI underwriting into its personal loan platform to widen access for a broader mix of consumers. See our latest analysis for Pagaya Technologies. This Achieve deal lands as Pagaya’s share price sits at $22.93. Strong year to date share price returns suggest momentum is still constructive despite a sharp 90 day share price pullback and a hefty one year total shareholder...

Wondering if Bank of America at around $54 is still a smart buy, or if you are turning up late to the party? This breakdown will help you decide whether the current price makes long term sense. The stock has slipped about 1.6% over the last week, but is still up 4.3% over the past month and a strong 22.5% year to date, with a 25.7% gain over the last year and more than doubling over five years. Those moves have come as investors weigh shifting macro conditions, from changing interest rate...

AbCellera Biologics (ABCL) just took a legal overhang off the table by signing a global settlement and patent license deal with Bruker that brings in $36 million upfront plus future royalties. See our latest analysis for AbCellera Biologics. The legal clean up helps explain why the 1 day share price return jumped 5.37 percent, even as the 90 day share price return is still down 21.73 percent. With a 23.86 percent 1 year total shareholder return versus a deeply negative 3 year total...

In recent days, Arm Holdings has faced pressure after high-profile analysts at firms including Mizuho Securities and Goldman Sachs downgraded the stock, citing limited leverage to the AI cycle and challenges in its evolving business model. At the same time, China’s progress toward extreme ultraviolet lithography and semiconductor self-sufficiency has raised fresh questions about long-term competitive positioning across Arm’s ecosystem, even as some analysts still emphasize structural growth...

Enphase Energy (ENPH) just expanded a safe harbor agreement with a major third party solar financier, a deal expected to bring in about 55 million dollars between late 2025 and early 2026. See our latest analysis for Enphase Energy. That backdrop helps explain why the stock’s 1 month share price return of 22.57% looks like a rebound in progress, even though the year to date share price return and 1 year total shareholder return are both still deeply negative. This suggests sentiment is...

If you are wondering whether HCI Group is still a smart buy after its huge run up, or if you might be late to the party, this article will help you weigh what the current price really bakes in. The stock has climbed 1.1% over the last week, 9.4% over the last month, and a hefty 65.6% year to date. Longer term holders have seen 69.0% over 1 year, 405.4% over 3 years, and 305.1% over 5 years. This naturally raises questions about how much upside is left versus downside risk. Recent headlines...

Wondering if Targa Resources at around $178 a share is still a smart buy or if most of the upside is already priced in? You are not the only one trying to sort out whether this run has more to give. The stock has slipped about 2.5% over the last week but is still up roughly 5.0% over the past month and 3.3% over the last year, on top of a massive 160.5% 3‑year and 643.2% 5‑year gain that has completely changed how the market sees its growth and risk profile. Those moves are happening against...

Wondering if Altria Group at around $58 a share is still a bargain or if the easy money has already been made? This breakdown will walk you through what the numbers are really saying about its value today. Despite a modest pullback of about 0.6% over the last week and 0.4% over the last month, the stock is still up 11.2% year to date, 16.4% over the past year and an impressive 102.9% over five years, which naturally raises the question of whether the current price still offers upside. Recent...

DSC Meridian Capital’s fresh stake in Elme Communities (ELME) comes shortly after Elme’s roughly $1.6 billion sale of 19 multifamily properties, a move that is sharpening investor focus on underlying asset value. See our latest analysis for Elme Communities. With the portfolio sale reframing Elme as a leaner multifamily REIT, the stock’s roughly 15 percent year to date share price return and near 20 percent one year total shareholder return suggest that momentum is quietly rebuilding as...

Customers Bancorp (CUBI) has been quietly rewarding patient shareholders, with the stock climbing about 20% over the past month and more than 60% this year. This performance is prompting a closer look at what is driving the move. See our latest analysis for Customers Bancorp. At around $77.91 per share, Customers Bancorp’s strong recent 1 month share price return sits on top of an already impressive multi year total shareholder return record. This may indicate that momentum is still building...

Earlier this week, JPMorgan upgraded Shake Shack from Underweight to Neutral, citing the chain’s evolution into a free cash flow positive business and a stronger financial profile. The shift to generating free cash flow marks an important milestone for Shake Shack, potentially giving the company more flexibility to fund its ambitious expansion plans. Next, we’ll explore how this newfound free cash flow strength could influence Shake Shack’s longer-term investment narrative and growth...

MBX Biosciences (MBX) slipped onto more traders radars after Goldman Sachs launched coverage with a bearish stance, questioning how much value the company can prove beyond its lead hormone therapy canvuparatide. See our latest analysis for MBX Biosciences. Despite Goldman’s cautious view, MBX’s recent 1 day share price return of 3.5 percent to 28.67 dollars comes after a powerful 90 day share price return of 186.7 percent and 1 year total shareholder return of 40.8 percent, suggesting...

Repligen (RGEN) just widened its bioprocessing toolkit with three new chromatography resins aimed at gene therapy workflows, a move that quietly matters for both long term growth expectations and the stock’s quality story. See our latest analysis for Repligen. Repligen’s new resin launches land after a bumpy stretch, with a strong 90 day share price return of 28.96 percent off a softer year to date base. However, the 1 year total shareholder return of 7.63 percent still masks a weaker multi...

Beam Therapeutics (BEAM) just updated investors on new safety and efficacy results from its BEACON Phase 1/2 trial in sickle cell disease, and the stock is reacting to what this means for future commercialization. See our latest analysis for Beam Therapeutics. The latest BEACON update lands after a choppy year, with a 24.74% 1 month share price return but a 1 year total shareholder return of negative 9.79%. This suggests that near term momentum is improving even as longer term holders remain...